Experimental T-817MA Therapy Currently Being Tested for Mild to Moderate Alzheimer’s Disease

Experimental T-817MA Therapy Currently Being Tested for Mild to Moderate Alzheimer’s Disease
A Phase 2 randomized, double blind, placebo-controlled, parallel group study is currently enrolling at multiple test centers in the United States to evaluate the efficacy and safety of T-817MA as a potential treatment in patients with mild to moderate Alzheimer’s disease. This study is a joint phase II clinical trial between lead partner Toyama ChemicalCo.,

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *